Schering-Plough clinical trials
Acquired by Merck & Co., Inc, Nov 3, 2009 · source ↗
The registry lists 10 studies whose lead sponsor is Schering-Plough. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 3, 2009.
Before and after it joined Merck & Co., Inc
- First submitted before Schering-Plough became part of Merck & Co., Inc
- 10
- First submitted after Schering-Plough became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Schering-Plough10 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Merck & Co., Inc studies →
- A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)WithdrawnNCT00060554Phase 2
Sponsor listed in the registry: Schering-Plough · First submitted before Schering-Plough became part of Merck & Co., Inc
- A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)CompletedNCT00394966Phase 2
Sponsor listed in the registry: Schering-Plough · First submitted before Schering-Plough became part of Merck & Co., Inc
- Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)CompletedNCT00705263
Sponsor listed in the registry: Schering-Plough · First submitted before Schering-Plough became part of Merck & Co., Inc
- Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)TerminatedNCT00491374Phase 4
Sponsor listed in the registry: Schering-Plough · First submitted before Schering-Plough became part of Merck & Co., Inc
- Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)CompletedNCT00811226
Sponsor listed in the registry: Schering-Plough · First submitted before Schering-Plough became part of Merck & Co., Inc
- PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)CompletedNCT00724620Phase 4
Sponsor listed in the registry: Schering-Plough · First submitted before Schering-Plough became part of Merck & Co., Inc
- Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive PatientsCompletedNCT00002446Phase 3
Sponsor listed in the registry: Schering-Plough · First submitted before Schering-Plough became part of Merck & Co., Inc
- Safety and Effectiveness of PEG-Intron in HIV-Infected PatientsCompletedNCT00005012Phase 2
Sponsor listed in the registry: Schering-Plough · First submitted before Schering-Plough became part of Merck & Co., Inc
- Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV RetinitisCompletedNCT00002070Phase 3
Sponsor listed in the registry: Schering-Plough · First submitted before Schering-Plough became part of Merck & Co., Inc
- A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive PatientsCompletedNCT00002399Phase 2
Sponsor listed in the registry: Schering-Plough · First submitted before Schering-Plough became part of Merck & Co., Inc